A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.

Saved in:
Bibliographic Details
Title: A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Authors: Algazi AP; University of California-San Francisco, San Francisco, California, USA., Moon J; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Southwest Oncology Group Statistical Center, Seattle, Washington, USA., Lao CD; University of Michigan, Ann Arbor, Michigan, USA., Chmielowski B; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA., Kendra KL; The Ohio State University Wexner Medical Center, Columbus, Ohio, USA., Lewis KD; University of Colorado Comprehensive Cancer Center, Denver, Colorado, USA., Gonzalez R; University of Colorado Comprehensive Cancer Center, Denver, Colorado, USA., Kim K; California Pacific Medical Center Research Institute, San Francisco, California, USA., Godwin JE; Providence Cancer Institute, Portland, Oregon, USA., Curti BD; Providence Cancer Institute, Portland, Oregon, USA., Latkovic-Taber M; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Lomeli SH; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA., Gufford BT; Labcorp Drug Development Inc., Madison, Wisconsin, USA., Scumpia PO; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA., Lo RS; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA., Othus M; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Ribas A; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, USA.
Source: Cancer [Cancer] 2024 May 15; Vol. 130 (10), pp. 1784-1796. Date of Electronic Publication: 2024 Jan 23.
Publication Type: Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-0142
DOI:10.1002/cncr.35200